BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 30367443)

  • 1. In vitro antitumor activity of progesterone in human adrenocortical carcinoma.
    Fragni M; Fiorentini C; Rossini E; Fisogni S; Vezzoli S; Bonini SA; Dalmiglio C; Grisanti S; Tiberio GAM; Claps M; Cosentini D; Salvi V; Bosisio D; Terzolo M; Missale C; Facchetti F; Memo M; Berruti A; Sigala S
    Endocrine; 2019 Mar; 63(3):592-601. PubMed ID: 30367443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxic Effect of Progesterone, Tamoxifen and Their Combination in Experimental Cell Models of Human Adrenocortical Cancer.
    Rossini E; Tamburello M; Abate A; Beretta S; Fragni M; Cominelli M; Cosentini D; Hantel C; Bono F; Grisanti S; Poliani PL; Tiberio GAM; Memo M; Sigala S; Berruti A
    Front Endocrinol (Lausanne); 2021; 12():669426. PubMed ID: 33981288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study.
    Fiorentini C; Fragni M; Perego P; Vezzoli S; Bonini SA; Tortoreto M; Galli D; Claps M; Tiberio GA; Terzolo M; Missale C; Memo M; Procopio G; Zaffaroni N; Berruti A; Sigala S
    J Clin Endocrinol Metab; 2016 Dec; 101(12):4594-4602. PubMed ID: 27626976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ribociclib Cytotoxicity Alone or Combined With Progesterone and/or Mitotane in in Vitro Adrenocortical Carcinoma Cells.
    Abate A; Rossini E; Tamburello M; Laganà M; Cosentini D; Grisanti S; Fiorentini C; Tiberio GAM; Scatolini M; Grosso E; Hantel C; Memo M; Berruti A; Sigala S
    Endocrinology; 2022 Feb; 163(2):. PubMed ID: 34875044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells.
    Gagliano T; Gentilin E; Benfini K; Di Pasquale C; Tassinari M; Falletta S; Feo C; Tagliati F; Uberti ED; Zatelli MC
    Endocrine; 2014 Dec; 47(3):943-51. PubMed ID: 25096913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro cytotoxicity of cabazitaxel in adrenocortical carcinoma cell lines and human adrenocortical carcinoma primary cell cultures
    Fragni M; Palma Lopez LP; Rossini E; Abate A; Cosentini D; Salvi V; Vezzoli S; Poliani PL; Bosisio D; Hantel C; Tiberio GAM; Grisanti S; Memo M; Terzolo M; Berruti A; Sigala S
    Mol Cell Endocrinol; 2019 Dec; 498():110585. PubMed ID: 31536779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of mitotane and 1α,25-dihydroxyvitamin D
    Rubin B; Pilon C; Pezzani R; Rebellato A; Fallo F
    J Endocrinol Invest; 2020 Mar; 43(3):357-367. PubMed ID: 31587178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells.
    Kroiss M; Sbiera S; Kendl S; Kurlbaum M; Fassnacht M
    Horm Cancer; 2016 Dec; 7(5-6):345-355. PubMed ID: 27631436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells.
    Sbiera S; Leich E; Liebisch G; Sbiera I; Schirbel A; Wiemer L; Matysik S; Eckhardt C; Gardill F; Gehl A; Kendl S; Weigand I; Bala M; Ronchi CL; Deutschbein T; Schmitz G; Rosenwald A; Allolio B; Fassnacht M; Kroiss M
    Endocrinology; 2015 Nov; 156(11):3895-908. PubMed ID: 26305886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma.
    Germano A; Rossin D; Leoni V; Iaia N; Saba L; Basile V; Puglisi S; Caccia C; Poli G; Biasi F; Terzolo M
    Cells; 2020 Apr; 9(4):. PubMed ID: 32260362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiation of mitotane action by rosuvastatin: New insights for adrenocortical carcinoma management.
    Boulate G; Amazit L; Naman A; Seck A; Paci A; Lombes A; Pussard E; Baudin E; Lombes M; Hescot S
    Int J Oncol; 2019 Jun; 54(6):2149-2156. PubMed ID: 30942448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational analyses of epidermal growth factor receptor and downstream pathways in adrenocortical carcinoma.
    Hermsen IG; Haak HR; de Krijger RR; Kerkhofs TM; Feelders RA; de Herder WW; Wilmink H; Smit JW; Gelderblom H; de Miranda NF; van Eijk R; van Wezel T; Morreau H
    Eur J Endocrinol; 2013 Jul; 169(1):51-8. PubMed ID: 23585556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Human Adrenocortical Cancer Cell Growth by Temozolomide in Vitro and the Role of the MGMT Gene.
    Creemers SG; van Koetsveld PM; van den Dungen ES; Korpershoek E; van Kemenade FJ; Franssen GJ; de Herder WW; Feelders RA; Hofland LJ
    J Clin Endocrinol Metab; 2016 Dec; 101(12):4574-4584. PubMed ID: 27603910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma.
    Satoh K; Zhang L; Zhang Y; Chelluri R; Boufraqech M; Nilubol N; Patel D; Shen M; Kebebew E
    Clin Cancer Res; 2016 Jul; 22(14):3458-66. PubMed ID: 26873959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines.
    Germano A; Rapa I; Volante M; Lo Buono N; Carturan S; Berruti A; Terzolo M; Papotti M
    Mol Cell Endocrinol; 2014 Jan; 382(1):1-7. PubMed ID: 24018612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statins Reduce Intratumor Cholesterol Affecting Adrenocortical Cancer Growth.
    Trotta F; Avena P; Chimento A; Rago V; De Luca A; Sculco S; Nocito MC; Malivindi R; Fallo F; Pezzani R; Pilon C; Lasorsa FM; Barile SN; Palmieri L; Lerario AM; Pezzi V; Casaburi I; Sirianni R
    Mol Cancer Ther; 2020 Sep; 19(9):1909-1921. PubMed ID: 32546662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging drugs for adrenocortical carcinoma.
    Berruti A; Ferrero A; Sperone P; Daffara F; Reimondo G; Papotti M; Dogliotti L; Angeli A; Terzolo M
    Expert Opin Emerg Drugs; 2008 Sep; 13(3):497-509. PubMed ID: 18764725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma.
    Doghman M; Lalli E
    Mol Cell Endocrinol; 2013 Dec; 381(1-2):66-9. PubMed ID: 23906534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenomic analysis in adrenocortical carcinoma reveals genetic features associated with mitotane sensitivity and potential therapeutics.
    Zhang J; Wu L; Su T; Liu H; Jiang L; Jiang Y; Wu Z; Chen L; Li H; Zheng J; Sun Y; Peng H; Han R; Ning G; Ye L; Wang W
    Front Endocrinol (Lausanne); 2024; 15():1365321. PubMed ID: 38779454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures.
    van Koetsveld PM; Creemers SG; Dogan F; Franssen GJH; de Herder WW; Feelders RA; Hofland LJ
    J Clin Endocrinol Metab; 2020 Feb; 105(2):407-17. PubMed ID: 31586196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.